Merck advances along a broad PhIII front, aimed at carving up Pfizer’s top-selling vaccine franchise. Could an ambush lay in wait?
Merck has come out of its corner with a 1-2 late-stage punch aimed at one of Pfizer’s biggest franchises. And they’re rolling the late-stage data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
